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EFFECTS OF MEDICAL THERAPY, ALCOHOL,
SMOKING, AND ENDOCRINE DISRUPTORS ON
MALE INFERTILITY
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Eleonora Bedin Pasqualotto and Sami Arap
PASQUALOTTO FF et al. Effects of medical therapy, alcohol, smoking, and endocrine disruptors on male infertility. Rev.
Hosp. Clín. Fac. Med. S. Paulo 59(6):375-382, 2004.
Infertility affects up to 15% of the sexually active population, and in 50% of cases, a male factor is involved, either as
a primary problem or in combination with a problem in the female partner. Because many commonly encountered drugs
and medications can have a detrimental effect on male fertility, the medical evaluation should include a discussion
regarding the use of recreational and illicit drugs, medications, and other substances that may impair fertility. With the
knowledge of which drugs and medications may be detrimental to fertility, it may be possible to modify medication
regimens or convince a patient to modify habits to decrease adverse effects on fertility and improve the chances of
achieving a successful pregnancy.
Concern is growing that male sexual development and reproduction have changed for the worse over the past 30 to
50 years. Although some reports find no changes, others suggest that sperm counts appear to be decreasing and that the
incidence of developmental abnormalities such as hypospadias and cryptorchidism appears to be increasing, as is the
incidence of testicular cancer. These concerns center around the possibility that our environment is contaminated with
chemicals – both natural and synthetic – that can interact with the endocrine system.
KEYWORDS: Semen. Endocrine. Sperm. Alcohol. Cigarettes. Drugs.
Lately, there has been increasing
concern about the potential of sub-
stances in the environment to disrupt
endocrine systems in humans and wild-
life.1-4 The primary emphasis to date
has been on substances that might
mimic estrogen and could interfere
with the normal functioning of the en-
docrine system. The list of chemicals
that are known to affect reproduction
in humans via endocrine mechanisms
include pesticides (DDT and its
metabolites), polychlorinated
biphenyls, dioxins, naturally occurring
plant estrogens (phytoestrogens), and
mycotoxins.5-8 Several other chemicals
(e.g. alkylphenols and phthalates)
have been shown to interfere with en-
docrine-mediated processes, but evi-
dence for effects on reproductive func-
tions in vivo is lacking. Current meth-
ods for assessing human and wildlife
health effects are generally targeted at
detecting effects rather than mecha-
nisms and may not adequately evalu-
ate effects on endocrine system.1,5,6
Infertility affects up to 15% of the
sexually active population, and in
50% of cases, a male factor is involved,
either as a primary problem or in com-
bination with a problem in the female
partner.9 Complete evaluation of the
male includes a detailed, directed his-
tory evaluating for specific risk factors
that may impair fertility, a directed
physical examination, and laboratory
testing. Because many commonly en-
countered drugs and medications can
have a detrimental effect on male fer-
tility, the medical evaluation should
include a discussion regarding the use
of recreational and illicit drugs, medi-
cations, and other substances used by
the patient that may adversely affect
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fertility.5,6 Equipped with the knowl-
edge of which drugs and medications
may be detrimental to fertility, it may
be possible to modify medication regi-
mens or convince a patient to modify
habits to decrease adverse effects on
fertility and improve the chances of
achieving a successful pregnancy.
Basically, there are 4 mechanisms
by which drugs and medications im-
pair male fertility: by exerting a
gonadotoxic effect on the testicles, by
altering the hypothalamic-pituitary-
gonadal (HPG) axis, by impairing
ejaculation and erectile function, and
by decreasing libido.10
Gonadotoxins directly affect tes-
ticular sperm production, resulting in
suboptimal sperm density, maturation,
motility, or morphology.10-13 Several
substances alter the delicately balanced
HPG axis, causing either a decline in
pituitary-secreted gonadotropins or an
alteration in intratesticular testosterone
concentrations.1 Ejaculation may be
impaired by drugs that cause retrograde
ejaculation, block spinal reflexes, or in-
hibit emission, resulting in a dry ejacu-
late. Erectile dysfunction may occur
with drugs that interfere with either neu-
rologic or vascular mediated events
necessary for normal erection to occur.
Finally, several medications interfere
with normal male libido through their
actions on the central nervous system
(CNS).1,5,6
Recreational and illicit drugs
Agents in this category that can af-
fect male fertility include alcohol, to-
bacco, and illicit drugs.
Alcohol
Long-term effects of chronic alco-
hol use include erectile dysfunction,
reduced libido, and gynecomastia.14
One mechanism of these effects is a re-
duction in serum testosterone caused
by decreased testicular production and
increased metabolic clearance in the
liver. It is thought that alcoholism and
hepatic cirrhosis cause alterations in
the HPG axis, resulting in testicular
dysfunction.14 In addition, the oxida-
tion of alcohol competes with testicu-
lar production of testosterone. These
mechanisms lead to subsequent de-
crease in semen volume and sperm
density. Another factor appears to be
an elevation in serum estrogen caused
by peripheral conversion of testoster-
one to estrogen through increased ac-
tivity of the enzyme aromatase, which
is present both in the liver and in pe-
ripheral fat cells.15
“Social” or light alcohol ingestion
does not appear to interfere with semen
quality.6 However, excessive acute al-
cohol intake does have adverse effects
on male fertility by causing decreased
serum testosterone concentrations. Im-
pairment of spinal reflexes, also caused
by excessive alcohol abuse, leads to
reduced sensation and innervation of
the penis, and thus may also contrib-
ute to erectile dysfunction.14
Cigarette smoking
Many studies have examined the
effects of cigarette smoking on fertil-
ity, and cumulative evidence suggests
that smoking has a significant negative
impact on sperm production, motility,
and morphology.6 Several reports
demonstrated that the mutagenic and
carcinogenic components of cigarette
smoke have adverse effects on rapidly
dividing cells, including germ cells in
the testis.16 However, recently we ob-
served that no differences were seen in
testicular volume, FSH and testoster-
one levels, or sperm concentration,
motility, and morphology in a popu-
lation of fertile patients who smoke or
drink coffee compared to patients that
do not have these habits.17
Animal studies have shown that
nicotine, cigarette smoke, and/or poly-
cyclic aromatic hydrocarbons can
cause testicular atrophy, poor sperm
morphology, and overall impaired
spermatogenesis, leading to the pres-
ence of oligospermia (<20 x 106 sperm/
mL or <40 x 106 sperm) and teratosper-
mia (<4% normal sperm forms). Serum
levels of prolactin and estradiol (E2)
are also elevated in smokers. This was
most pronounced in smokers who had
low sperm counts compared to smok-
ers who had normal sperm counts.
Estradiol impairs spermatogenesis via
several different mechanisms, includ-
ing alteration of the HPG axis. Stud-
ies have also show that elevated E2
levels can cause increased catecho-
lamine levels, which in turn can pro-
duce ischemia of the seminiferous tu-
bules. While the exact mechanism for
the apparent elevation in E2 in smok-
ers is unknown, it appears to be due
to increased production of this hor-
mone rather than to decreased meta-
bolic clearance.
It has been reported that cigarette
smoking causes increased serum lev-
els of norepinephrine, which in turn
can increase aromatization of testo-
sterone to E2 in Sertoli cells in vitro.18
While it is unclear exactly how smok-
ing directly affects spermatogenesis,
overwhelming evidence suggests that
it has an unfavorable impact on fertil-
ity. Thus, every effort should be made
to counsel both partners to stop the use
of tobacco as part of their infertility
treatment.
Illicit drugs
Several illicit drugs are detrimen-
tal to male fertility and should be
avoided, especially in men trying to
establish a pregnancy.10 Marijuana in-
terferes with spermatogenesis by de-
creasing sperm density and motility
and decreasing the number with mor-
phologic abnormalities.19 High doses
of opiates lead to a decline in libido
and erectile function. Opiates suppress
the luteinizing hormone (LH) and
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luteinizing hormone releasing factor
(LH-RH), leading to a decline in tes-
tosterone production. The pituitary
gland itself may also be directly sup-
pressed by opiates. High doses of co-
caine impair erectile function, and
high doses of amphetamines have been
shown to cause diminished libido.6
Antihypertensives
While medical treatment of hyper-
tension is important, urologists treat-
ing male infertility must be knowl-
edgeable about the agents that cause
the most significant impairments in
testicular function.6,10 While fertility
remains desirable, men using these
medications can often be switched to
another class of antihypertensive
medications while attempting preg-
nancy.
Most antihypertensive agents exert
a deleterious effect on fertility by im-
pairing sexual function. However it is
important to keep in mind that hyper-
tension occurs more commonly in the
older population, a group known to
have a higher incidence of erectile
dysfunction in general. The use of
antihypertensives in conjunction with
vascular insufficiency may exacerbate
inadequate blood flow to the male
genitals.19
Diuretics such as the thiazides de-
crease blood flow to the penis by re-
ducing vascular resistance.6,10 Pro-
pranolol has been noted to cause a de-
crease in both libido and erectile func-
tion.6,10,19 Cardioselective agents such
as atenolol and metoprolol appear to
have less deleterious effects on male
sexual function. Vasodilators them-
selves do not inhibit sexual function
because they do not interfere with
sympathetic reflexes. However, they
are often used in conjunction with
beta-blockers and diuretics that do af-
fect potency and libido. Efforts should
be made to refer patients back to their
clinicians to change beta-blockers to
other agents such as angiotensin con-
verting enzyme (ACE) inhibitors.
Due to its effect on the HPG axis,
spironolactone may cause profound fer-
tility problems. This agent also pre-
vents the binding of dihydrotestos-
terone (DHT) to its receptor and inhib-
its the production of testosterone,
which may result in reduced libido,
erectile dysfunction, and significantly
decreased sperm production.6,10,19
Calcium channel blockers
Calcium influx is critical for the
normal acrosome reaction to occur.20
Thus, calcium channel blocking
(CaCB) medications have recently re-
ceived particular attention as potential
inhibitors of the normal fertilization
process. The calcium influx required
during the acrosome reaction may be
impaired directly by the effects of
CaCBs or by insertion of the CaCBs
into the plasma membrane of the sperm
head. This insertion causes an altera-
tion in the surface molecules expressed
on the sperm head that are also re-
quired for normal fertilization to oc-
cur.20,21
Clinical studies have shown that
cessation of the CaCB may reverse
this process and restore the fertility in
some otherwise infertile men. Other re-
ports, however, have failed to show any
adverse effect of CaCBs on male fer-
tility.22 While the effects of CaCBs on
male fertility remains unclear, it may
be prudent to discuss a switch to an-
other antihypertensive agent with pa-
tients who are taking these medica-
tions and who desire fertility.
Alpha-adrenergic blockers
Agents such as alfuzosin,
tamsulosin, terazosin, and doxazosin
are commonly prescribed for the treat-
ment of benign prostatic hyperplasia,
and are also used in younger men with
voiding complaints. They function by
blocking the motor sympathetic adren-
ergic nerve supply to the prostate, re-
sulting in a reduction in urethral pres-
sure.23 Differences in affinity for the a-
receptor subtypes determine the side-
effect profile for the individual agents.
The more selective alpha-blocking
agents, by reducing smooth muscle
tone at the bladder neck, can cause ret-
rograde ejaculation.6 While patients
tend to better tolerate and are more
compliant with alfuzosin and
tamsulosin than doxazosin, terazosin,
and prazosin, retrograde ejaculation is
more commonly associated with
tamsulosin, occurring in about 8.5% of
men. While ganglion blockers (meth-
yldopa, guanethidine, and reserpine)
can have similar side effects on male




Agents such as captopril and
enalapril have not been associated
with male sexual dysfunction or infer-
tility, nor have direct vasodilators ef-




much of their effect on male fertility




dopamine in the CNS, leading to sup-
pression of the HPG axis and decreased
libido. Some antipsychotic agents also
have alpha-adrenergic blocking effects
that block innervation of the internal
genital organs. In addition, some are
vasodilators that can redirect blood
away from the penis and cause erectile
dysfunction. It is important to realize,
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however, that antipsychotics can bring
about important changes in overall
well-being that may far outweigh any
of the deleterious effects mentioned
above.14,19
Tricyclic antidepressants
The use of tricyclic antidepressants
or selective serotonin reuptake inhibi-
tors (SSRIs) can lead to erectile dys-
function and reduced libido through
their anticholinergic and sedative side
effects.6,14,19 They have also been
shown to impair ejaculation. Because
these agents cause a delay in ejacula-
tion, they have been used to treat men
with premature ejaculation.
Perhaps the most significant side
effect of antidepressants, however, is
the potential for substantial elevation
in serum prolactin concentrations.
Hyperprolactinemia suppresses secre-
tion of gonadotropin releasing hor-
mone (GnRH) from the hypothalamus,
and the high prolactin levels inhibit
LH from binding to Leydig cells in the
testes. These actions lead to significant
but reversible suppression of sperma-
togenesis. If fertility is desired, the ini-
tial treatment of hyperprolactinemia
caused by antidepressant use is a
change to another class of medication.
However, if this is not possible,




hyperprolactinemia and negatively af-
fect male fertility in the same way as
tricyclic antidepressants; thus, treat-
ment is similar.6,10,14,19 Monoamine oxi-
dase inhibitors, another prominent
class of antidepressants, can cause
erectile dysfunction or ejaculatory
problems. Finally, lithium carbonate
has been shown to decrease the action
of dopamine in the CNS, causing de-
creased libido and potency.
Chemotherapeutic agents
The use of chemotherapeutic agents
is necessary in the treatment of many
malignancies that occur in young men,
including Hodgkin’s lymphoma, tes-
ticular cancer, and acute lymphocytic
leukemia.6,10,24-26 Chemotherapeutic
agents have the potential to damage
both germ cells and the supporting Ser-
toli cells, leading to severe oligosper-
mia or azoospermia immediately fol-
lowing most courses of chemotherapy.
While Leydig cells are less susceptible
to injury than Sertoli cells, they may
still demonstrate a degree of dysfunc-
tion, resulting in increased LH levels
and low-normal testosterone levels. The
most gonadotoxic chemotherapeutic
agents include alkylating agents (cy-
clophosphamide, chlorambucil, and
busulfan), antimetabolites (cytarabine),
vinca alkaloids (vinblastine), and oth-
ers (cisplatin, procarbazine, mechlo-
rethamine).27-29
While nearly all men will have pro-
found defects in spermatogenesis im-
mediately following chemotherapy,
the ability to regain spermatogenesis
following treatment varies depending
on the individual agents used, the dose
of each, and the length of treatment.
Clearly, total destruction of the sper-
matogenic stem cells populating the
testes leads to permanent sterility.
However, it is often possible to limit
damage to these chemosensitive cells
by using combination therapies in
which the individual dosages of the
most toxic agents are reduced.24-29
During treatment with chemothera-
peutic agents, attempts should be
made to minimize damage to sperm-
producing cells. One way to accom-
plish this is to use alternative chemo-
therapeutic agents such as methotrex-
ate, which seems to be less harmful to
testicular germ cells. Another way to
decrease gonadotoxicity is to reduce
the dose of alkylating agents and the
number of cycles.27,28
It is not always possible to restore
spermatogenesis following chemo-
therapy.24-26 It is therefore essential to
offer patients the option of sperm
cryopreservation prior to the initiation
of chemotherapy. While some of these
patients may have suboptimal semen
quality prior to treatment, the use of
in vitro fertilization technology cou-
pled with intracytoplasmic sperm in-
jection offers many men, even those
with very low levels of sperm produc-
tion, the potential to achieve a bio-
logic pregnancy.24-26,29
Animal studies have shown that the
use of certain hormonal treatments
during the administration of cytotoxic
chemotherapy may provide protective
effects to germ cells. GnRH analogues
and testosterone combine to suppress
the concentration of intratesticular tes-
tosterone. When giving during cyto-
toxic chemotherapy, this type of treat-
ment does not protect spermatogonia
from damage. Rather, it appears to ac-
celerate the return of sperm production
after treatment is completed. Hormonal
treatment may “desensitize” support-
ing cells of the testis, making them
less susceptible to harm from cytotoxic
therapy, thereby enabling recovery of
spermatogenesis. The primary support-
ing cell, but Leydig cells also appear
to be involved. Further studies are nec-
essary to demonstrate whether these
protective effects will also be achieved
in humans.30-32
Hormones
Several hormonal agents influence
male fertility, including anabolic ster-
oids, testosterone replacement thera-
pies, and antiandrogens.
Anabolic steroids
Anabolic steroids are being used
not only by body builders, but also by
athletes in all age groups. Unfortu-
nately, these agents may have devas-
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tating effects on fertility. Anabolic ster-
oids suppress the HPG axis via feed-
back inhibition.10 This causes severely
reduced production of follicle-stimu-
lating hormone (FSH) and LH result-
ing in hypogonadotropic hypogonad-
ism.14 Steroid use may also cause erec-
tile dysfunction by decreasing produc-
tion of endogenous testosterone. High
doses of anabolic steroids have also
been shown to decrease sperm density
and motility and increase morpho-
logic abnormalities.
Fortunately, sperm production is
likely to recover once steroid use is
discontinued. While it generally takes
4 months for semen parameters to re-
turn to baseline levels, the continued
presence of azoospermia has been re-
ported 1 year after discontinuing ana-
bolic steroid use.6,10 During this time,
some men may benefit from injectable
gonadotropins, such as human chori-
onic gonadotropin (hCG) replacement,
to help stimulate sperm production
and maintain endogenous testosterone
production.
Testosterone production
With the increasing availability of
safe, well-tolerated treatment methods,
testosterone replacement therapy has
become more common in clinical
medicine. However, the use of exog-
enous androgens impairs spermatogen-
esis by inhibiting the HPG axis.6,10,14,19
Testosterone is also converted to
estrogen in peripheral fat cells by the
enzyme aromatase, increasing the
negative feedback on the HPG axis. In
men with decreased serum testosterone
concentrations who wish to remain fer-
tile, testosterone replacement in its
various forms should not be used. An
alternative in younger men with de-
creased serum testosterone concentra-
tions is treatment with gonadotropins
(such as hCG) or with the centrally-
acting antiestrogen, clomiphene
citrate. This agent has the advantage
of being available in an oral form,
while hCG requires repeated subcuta-
neous injection. However, both of
these treatments will improve serum
and intratesticular testosterone con-
centrations without decreasing gona-
dotropin levels through feedback in-
hibition.
Other hormonal therapies
Estrogens have been used in the
past to treat advanced prostate cancer
in men. Effects on sexual function in-
clude decreased libido, feminization,
erectile dysfunction, and testicular at-
rophy. Finasteride is frequently used
by men of reproductive age for its pre-
ventative effects on male-pattern bald-
ness.33 While the use of this medica-
tion could conceivably alter
intratesticular testosterone concentra-
tions, there appears to be no evidence
for any alteration in semen quality.
Saw palmetto is a commonly used
herbal agent for symptoms of bladder
outlet obstruction. While its mecha-
nisms of action is largely unknown, it
appears that it may exert some of its
beneficial effect through slight
estrogenic activity or by blocking the
conversion of testosterone to DHT.34
While these effects could theoretically
impair sperm production or function,
no studies have yet been performed to
evaluate this.
Antibiotics
Several commonly prescribed anti-
biotics may adversely affect fertility.
Classically, high doses of nitrofuran-
toin have been shown to cause matu-
ration arrest in the testis, most likely
by preventing testicular cells from us-
ing carbohydrates and oxygen.35 How-
ever, low-dose, short-term therapy with
nitrofurantoin has not been shown to
have these same adverse effects. Eryth-
romycin may reduce sperm motility
and density.35,36 Due to the fact that
tetracyclines bind to mature spermato-
zoa, they have the potential to affect
sperm motility. While gentamicin and
neomycin may directly inhibit sperma-
togenesis, in vitro studies have failed
to show an effect on mature spermato-
zoa.
Semen Quality
Several reports in the literature
have suggested a possible decline in
human semen quality during the last
50 to 60 years.37-40 However, the de-
cline in sperm counts has been sus-
pected just to reflect changes in the
policy of infertility treatment, or a bias
in selection of patients, rather than a
biological phenomenon.
A systematic analysis of 61 stud-
ies was undertaken by Carlsen in
1992. It showed a significant decrease
in sperm concentration (from 113 mil-
lion/mL to 66 million/mL) and semen
volume (from 3.4 mL to 2.75 mL) over
the period 1938-1990.40 These results
have been discussed in the literature
and have stimulated extensive re-
search. In North America, the slope was
somewhat less than previously re-
ported. The decline in Europe was
even greater than previously reported,
whereas the few studies from other
continents showed no trend.37,38 These
results are consistent with those of
Carlsen et al. and indicate that, after
controlling for abstinence time, age,
percent of men with proven fertility,
and specimen collection method, there
is a negative trend in sperm production
in Europe and North America for the
period 1934 to 1996. Over this period
of time, the decrease is about 50%.
The larger single study undertaken
in this subject comes from the analysis
of 1351 healthy men volunteering for
sperm donation in the sperm bank of
Paris.38 After taking into account all po-
tential covariates, there remained a
yearly decrease of 2.6% in sperm con-
centration, 0.3% in percentage of motile
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sperm, and 0.7% in the percentage of
morphologically normal spermatozoa.
Testicular dysgenesis syndrome
Considerable concern has been
raised in recent publications that
estrogen-like compounds in either
food or the environment cause adverse
effects on reproductive health.1,3 There
is clear evidence that reproductive dis-
ruption in wildlife may be caused by




cancer, and poor semen quality have
also been proposed to be the symp-
toms of one underlying cause, the tes-
ticular dysgenesis syndrome, which
may develop during fetal life under
the influence of environmental fac-
tors.3 However, there is only circum-
stantial evidence in humans that expo-
sure to endocrine disrupters, especially
diethylstilbestrol (DES), during preg-
nancy causes problems of reproductive
health. The critical issue is whether
there are enough high levels of endo-
crine disrupters in the ambient.
When these observations are
brought together with the increasing
incidence of testicular cancer in all the
countries in which it is measured, and
with the reported increased incidence of
cryptorchidism and of hypospadias, the
existence of a single syndrome, the “tes-
ticular dysgenesis syndrome” (TDS),
that would associate these 3 elements,
seems likely. These anomalies (decreas-
ing sperm production, testicular cancer,
and male genital tract malformations)
are not necessarily associated in the
same individuals, but they are statisti-
cally linked at the population level;
however, one study showed that low
sperm concentration, poor spermatozoa
motility, and high proportion of mor-
phologically abnormal spermatozoa
were all associated with an increased
risk in testicular cancer.1-4
Hypospadias
There is some evidence for an in-
creased hypospadias rate during the
last few decades.43,44 Several explana-
tions have been proposed, including
increased exposure to endocrine dis-
ruptors during fetal life. Another pos-
sible explanation is that, since pub-
lished hypospadias rates are exclu-
sively derived from birth-defect regis-
tries, artefacts in these registries may
account for the reported changes over
time. Recently, Dolk et al., discussed
the possibility that the rise in hypos-
padias is caused by an increasing ten-
dency to report minor hypospadias.45
However, the hypothesis is difficult to
prove, since very few studies report the
total distribution of cases by severity.
Cryptorchidism
There are also indications that
cryptorchidism may have increased in
incidence in several countries, but in
general, cryptorchidism is registered
more unreliably than hypospadias.46
Also, this anomaly is regarded as be-
ing associated with exposure to endo-
crine disruptors in utero.
Transinguinal descent of the testes
also depends on androgens, but dis-
rupted androgen action can only ex-
plain a very small proportion of cases
with cryptorchidism.47 Neonatal expo-
sure to DES in male rats caused major
developmental abnormalities of the
testis, epididymis, vas deferens, semi-
nal vesicles, and prostate when evalu-
ated at the time of normal onset of pu-
berty.48
Testicular cancer
The most convincing evidence for
a gene decline in male reproductive
health in humans is the increase in
testicular cancer noted in the recent
past in several Western countries.4,27-29
Both cryptorchidism and hypospadias
are associated with an increased risk of
testicular cancer, based n the observa-
tion that men with cryptorchidism/
hypospadias are over-represented
among patients with testicular cancer.1
The hypothesis that endocrine dis-
ruption can cause cancer in humans is
based on the association between DES
exposure of pregnant women and clear
cell adenocarcinoma of the vagina and
cervix in their female offspring. Some
of the male offspring of women who
took DES show pseudohermaphro-
ditism and genital malformations, in-
cluding epididymal cysts, small testes,
microphallus, and reduced semen qual-
ity.49 Follow-up surveys of DES-ex-
posed male offspring have shown no
impairment in fertility or sexual func-
tion, or evidence of an increased risk
of testicular cancer. Dysgenic testes
have a very high risk of developing
testicular cancer in adulthood; these
cancers seem to arise from premalig-
nant gonocytes or in situ carcinoma
cells.1,29
RESUMO
PASQUALOTTO FF e col. Efeitos da
terapia medicamentosa, àlcool,
cigarros e substância deletérias para
o sistema endócrino na infertili-
dade masculina. Rev. Hosp. Clín.
Fac. Med. S. Paulo 59(6):375-382,
2004.
A infertilidade afeta até 15% da
população sexualmente ativa e em
50% dos casos, o fator masculino está
envolvido, como problema primário ou
em combinação com causas de origem
feminina. Como muitas drogas
comumente encontradas e medicações
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podem ter efeitos deletérios na infer-
tilidade masculina, a avaliação médi-
ca deve incluir uma discussão sobre o
uso de drogas recreacionais e ilícitas,
medicamentos e outras substâncias po-
dem prejudicar a fertilidade. Com o
conhecimento de quais drogas e me-
dicamentos podem ser prejudiciais à
fertilidade talvez seja possível mudar
os hábitos ou a posologia das medica-
ções para diminuir os efeitos adversos
na fertilidade e aumentar as chances
de engravidar com sucesso.
Preocupações referentes ao desen-
volvimento sexual masculino e repro-
dução tem mudado para a pior nos úl-
timos 30-50 anos. Embora alguns rela-
tos não demonstrem modificações, ou-
tros sugerem que a concentração
espermática esteja diminuindo e que a
incidência de anormalidades do desen-
volvimento como hipospádia e
criptorquidia parecem estar aumentan-
do, assim como a incidência de câncer
de testículo. Estas preocupações sobre
a possibilidade do ambiente estar con-
taminado com substâncias químicas –
naturais ou sintéticas – que podem
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